# A Study to Evaluate SHR-1139 Injection in Patients With Pyoderma Gangrenosum

> **NCT07444684** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Guangdong Hengrui Pharmaceutical Co., Ltd** · enrollment: 20 (estimated)

## Conditions studied

- Pyoderma Gangrenosum

## Interventions

- **DRUG:** SHR-1139 Injection

## Key facts

- **NCT ID:** NCT07444684
- **Lead sponsor:** Guangdong Hengrui Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-05
- **Primary completion:** 2027-06
- **Final completion:** 2028-04
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07444684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07444684, "A Study to Evaluate SHR-1139 Injection in Patients With Pyoderma Gangrenosum". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07444684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*